CLINICAL TRIAL / NCT03319940

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

  • Interventional
  • Recruiting
  • NCT03319940

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)

A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC